Thorir Bjornsson - VP Early Devlopment & Clinical Pharmacology for Wyeth

Thorir joined Wyeth in 2001 from Bristol-Myers Squibb, where he had been Vice President, Clinical Pharmacology & Experimental Medicine. He is a graduate of University of Icelands Medical School. After initial clinical training, including hematology/oncology, he trained in clinical pharmacology at Stanford University Medical Center. He has held academic appointments at Duke University Medical Center, Durham, North Carolina, as Assistant/ Associate Professor of Medicine and Pharmacology, and at Jefferson Medical College, Philadelphia, Pennsylvania, as Professor of Medicine and Pharmacology, and Director of the Division of Clinical Pharmacology.

During his academic years at Duke and Jefferson, Thorir maintained an active research laboratory. Basic research interest areas have included the pharmacology of antithrombotic agents, fibrinogen, plasminogen activators, and amyloid β-peptide. Clinical research interests have included early clinical development and clinical pharmacology studies, ranging from First-in-Human studies and Proof-of-Concept studies, through Phase IIIb and Phase IV pharmacology studies. Other active interest areas include predictive models of efficacy, safety and compound properties; biomarkers and bioimaging; biosimulations; unmet medical need assessment; and strategic aspects of drug development.

He is the author or co-author of over 200 papers, book chapters and abstracts. He is the past recipient of numerous awards and honors, including Nanaline Duke Scholar at Duke University, and Samuel M.V. Hamilton Family Professor of Medicine (endowed chair) at Jefferson Medical College. He has been an active member in ASCPT and ASPET.

Category:

People & Blogs

Tags:

• Pharmacology
• Pharmaceutical Industry
• R&D Expenditures
• Wyeth
• MeettheBoss